WO2021001728A1 - Process for preparation of edoxaban - Google Patents

Process for preparation of edoxaban Download PDF

Info

Publication number
WO2021001728A1
WO2021001728A1 PCT/IB2020/055950 IB2020055950W WO2021001728A1 WO 2021001728 A1 WO2021001728 A1 WO 2021001728A1 IB 2020055950 W IB2020055950 W IB 2020055950W WO 2021001728 A1 WO2021001728 A1 WO 2021001728A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
formula
reaction mass
solvent
added
Prior art date
Application number
PCT/IB2020/055950
Other languages
French (fr)
Inventor
Prem Chand
Pramod Vitthal PATIL
Balasahab JADHAV
Sachin Mahadeo LAD
Samir Naik
Shekhar Bhaskar Bhirud
Nasir Ali Shafakat Ali
Original Assignee
Glenmark Life Sciences Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenmark Life Sciences Limited filed Critical Glenmark Life Sciences Limited
Priority to EP20834439.0A priority Critical patent/EP3993792A4/en
Priority to US17/624,595 priority patent/US20220251112A1/en
Publication of WO2021001728A1 publication Critical patent/WO2021001728A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Definitions

  • the present invention relates to a process for the preparation of edoxaban and salts thereof.
  • Savaysa (Edoxaban tosylate monohydrate) is /V-(5-chloropyridin-2-yl)-/V'- [(lS,2R,4S)-4 (/V,/V-dimethyl carbamoyl)- 2-(5-methyl-4,5,6,7-tetrahydro [1,3] thiazolo[5,4-c]pyridine-2-carboxamido)cyclohexyl]oxamide mono(4-methyl benzenesulfonate) monohydrate depicted by compound of formula I.
  • Savaysa is a factor Xa inhibitor, indicated to reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF). Savaysa is available as 15 mg, 30 mg and 60 mg oral tablets.
  • the present invention provides a simple and industrially advantageous process for preparing edoxaban.
  • compound of Formula IV is an important intermediate, prepared by the reaction of compound of formula V with a compound of formula VI.
  • the present invention provides a process for the preparation of edoxaban tosylate monohydrate, a compound of formula I, comprising: a) reacting the compound of formula V with a compound of formula VI in the presence of a base and a solvent to obtain compound of formula IV, wherein the solvent is dimethyl sulfoxide;
  • Fig. 1 XRD pattern of edoxaban tosylate monohydrate as obtained from example 4E.
  • Fig 2 XRD pattern of edoxaban free base as obtained from example 3E.
  • the present invention provides a process for the preparation of edoxaban tosylate monohydrate, a compound of formula I, comprising:
  • step b) reacting the compound of formula IV obtained in step a) with a deprotecting reagent to obtain a compound of formula II or salt thereof;
  • step b) reacting the compound of formula II or salt thereof obtained in step b) with a compound of formula III in the presence of a base to obtain a compound of formula I- A;
  • step d) reacting compound of formula I-A obtained in step c) with para toluene sulfonic acid in a solvent to obtain compound of formula I;
  • step a) the base is added in one lot.
  • the addition of base in one lot means the entire amount of base is added all at once in a single portion and is not added in parts.
  • the base in step a) is an amine and/or nitrogen- containing heterocyclic compounds.
  • the base is selected from the group consisting of triethyl amine, pyridine, alkane amines, such as methylamine, diisopropylamine; imidazole, benzimidazole, histidine, guanidine phosphazene, n-methyl morpholine, morpholine, n-methylpyrolidine and the like.
  • the base is triethyl amine.
  • the base used in step a) is added in one lot.
  • step a) the base, triethyl amine is not added in parts.
  • step a the reaction is carried out at a temperature in the range of 40 -80°C.
  • step a the reaction is carried out for a period of 1- 10 hours.
  • step a) the reaction is carried out at a temperature in the range of 50 -60°C for about 2-8 hours.
  • compound of formula IV is obtained in at least 90% yield with respect to compound of formula V.
  • compound of formula IV is obtained in a purity of at least
  • the deprotecting reagent is selected from ethyl acetate hydrochloride, hydrochloric acid, isopropyl alcohol HC1, methyl alcohol HC1, 1,4-dioxane HC1, ethanol HC1, isopropyl ether HC1, n-propanol HC1 and the like.
  • step b) the deprotecting agent is hydrochloric acid.
  • step b) the deprotection is carried out in a solvent selected from the group consisting of ethyl acetate, acetone, isopropyl alcohol, dioxane, methanol, dimethyl sulfoxide, tetrahydrofuran, toluene, xylene, methylene dichloride, dimethyl formamide and the like.
  • a solvent selected from the group consisting of ethyl acetate, acetone, isopropyl alcohol, dioxane, methanol, dimethyl sulfoxide, tetrahydrofuran, toluene, xylene, methylene dichloride, dimethyl formamide and the like.
  • the deprotecting agent used in step b) is selected from the group consisting of ethyl acetate hydrochloride in ethyl acetate solvent, hydrochloric acid in dioxane solvent and hydrochloric acid in acetone solvent.
  • step b) the deprotection is carried out using hydrochloric acid in acetone solvent.
  • step b) the compound of formula II obtained in step b) is a dihydrochloride salt, a compound of formula II-A
  • the reaction in step c), may be carried out in presence of a solvent selected from the group consisting of dioxane, methylene dichloride, ethyl acetate, dimethyl formamide, tetrahydrofuran, dimethyl sulfoxide.
  • a solvent selected from the group consisting of dioxane, methylene dichloride, ethyl acetate, dimethyl formamide, tetrahydrofuran, dimethyl sulfoxide.
  • step c) the reaction is carried out in presence of methylene dichloride solvent.
  • the base is an amine and/or nitrogen- containing heterocyclic compounds.
  • the base is selected from the group consisting of triethyl amine, diisopropylethyl amine, pyridine, alkane amines, such as methylamine, diisopropylamine, imidazole, benzimidazole, histidine, guanidine phosphazene bases, n-methyl morpholine, morpholine, n-methylpyrolidine and the like.
  • the base is either triethyl amine or diisopropyl amine.
  • step c) an activating agent may be used.
  • the activating agent may be selected from the group consisting of carbodiimides; 1- hydroxybenzotriazole based or l-hydroxy-7- azabenzotriazole based phosphonium and uronium salts; halouronium and halophosphonium salts; benzotriazine based uronium salts and phosphates; N- acylimidazoles; N-acyltriazoles and the like.
  • the carbodiimide activating agent may be selected from the group consisting of N, N’-dialkylcarbodiimides such as N, N’- dicyclohexylcarbodiimide (DCC) or diisopropylcarbodiimide (DIPC), l-ethyl-3-(3- dimethylaminopropyl)-carbodiimide (EDC) and the like.
  • N, N’-dialkylcarbodiimides such as N, N’- dicyclohexylcarbodiimide (DCC) or diisopropylcarbodiimide (DIPC), l-ethyl-3-(3- dimethylaminopropyl)-carbodiimide (EDC) and the like.
  • 1 -hydroxybenzotriazole and l-hydroxy-7-azabenzotriazole based phosphonium salt may be selected from the group consisting of benzotriazol-1- yl-N-oxy-tris(dimethylamino)phosphonium hexafluorophosphate (BOP), benzotriazol- 1 -yl-N-oxy-tris(pyrrolidino)phosphonium hexafluorophosphate
  • step c) the coupling agent is N, N’- dicyclohexylcarbodiimide (DCC) or EDC.HC1
  • step c) an additive may be used.
  • the additive may be selected from the group consisting of 1 -hydroxybenzotriazole (HOBt), l-hydroxy-7-azabenzotriazole (HOAt), 3,4-dihydro-
  • step c) is carried out in presence of dicyclohexylcarbodiimide (DCC) and 1 -hydroxybenzotriazole (HOBt).
  • DCC dicyclohexylcarbodiimide
  • HOBt 1 -hydroxybenzotriazole
  • the compound of formula I-A may be optionally purified by solvent selected from the group consisting of methanol, ethanol, isopropyl alcohol and n-butanol, water or mixtures thereof.
  • step d) the compound of formula I-A and para toluene sulfonic acid is suspended in a solvent selected from the group consisting of acetone, dimethyl sulfoxide, isopropyl alcohol, methanol, ethanol, water or mixture thereof.
  • step d) the amount of para toluene sulfonic acid added is 1.27 -1.3 molar equivalent with respect to edoxaban, a compound of formula I-A.
  • step d) the para toluene sulfonic acid is added in one lot.
  • step d) the compound of formula I-A and para toluene sulfonic acid are suspended in a solvent and heated to about 40 ° C to about 70 ° C.
  • step d) the compound of formula I-A and para toluene sulfonic acid is suspended in a solvent and heated to about 55°C to about 65°C for a period of about 1-2 hours, followed by filtration.
  • the filtrate is cooled to obtain the compound of formula I.
  • step e) the recrystallization of compound of formula I is carried out in a solvent selected from the group consisting of acetone, dimethyl sulfoxide, isopropyl alcohol, methanol, water or mixture thereof.
  • a solvent selected from the group consisting of acetone, dimethyl sulfoxide, isopropyl alcohol, methanol, water or mixture thereof.
  • the present invention provides a process for the preparation of edoxaban tosylate monohydrate, a compound of formula I comprising:
  • the present invention provides a process for the preparation of edoxaban tosylate monohydrate, a compound of formula I comprising:
  • the present invention provides a process for the preparation of edoxaban tosylate monohydrate, a compound of formula I comprising:
  • the non-nitrile solvent is selected from the group consisting of acetone, dioxane, isopropyl alcohol, tetrahydrofuran, toluene, dimethylformamide, dimethyl acetamide, dimethyl sulfoxide.
  • the present invention provides a compound of formula II- A
  • the present invention provides a process for the preparation of compound of formula II-A comprising:
  • the present invention provides a process for the preparation of compound of formula II-A comprising: a) reacting a compound of formula V with a compound of formula VI in the presence of a base and a solvent to obtain a compound of formula IV, wherein the solvent is dimethyl sulfoxide; and
  • HPLC method High performance liquid chromatography (HPLC) was performed with the conditions described below for detecting purity:
  • Example 1A Preparation of carbamic acid, N-[(1R, 2S, 5S)-2-[[2-[(5-chloro-2- pyridinyl) amino]-2-oxoacetyl] amino] -5- [(dime thy lamino) carbonyl] cyclohexyl]- 1, 1-dimethylethyl ester (compound of formula IV):
  • reaction mass was then cooled to about 25°C to 30°C. Water was then added to the reaction mass under stirring and the reaction mass was further cooled to about 0°C to 5°C and stirred for 120 minutes. The reaction mass was then filtered to obtain the product. The product obtained was washed with water and dried at about 45°C to 50°C for about 12 hours to obtain the compound of formula IV. Yield: 18g.
  • Example IB Preparation of carbamic acid, N-[(1R, 2S, 5S)-2-[[2-[(5-chloro-2- pyridinyl) amino]-2-oxoacetyl] amino] -5- [(dime thy lamino) carbonyl] cyclohexyl]- 1, 1-dimethylethyl ester (compound of formula IV):
  • reaction mass was then stirred at about 55°C to 60°C for about 5 hours, cooled to about 25°C to 30°C and stirred for about 12 hrs. After completion, water was added to the reaction mass under stirring and stirred for 180 minutes. Filtered the product, washed with water and dried at about 45°C to 50°C for about 12 hours to obtain the compound of formula IV.
  • the compound of formula IV (28.0g) was added to ethyl acetate and ethyl acetate hydrochloride (8-10%) was then added to it.
  • the reaction mass was heated to about 60°C to 70°C for about 3 hours.
  • the reaction mass was then cooled to about 25°C to 30°C.
  • the reaction mass was then filtered to obtain the product.
  • the product obtained was washed with ethyl acetate and dried at about 45°C to 50°C for about 12 hours to get compound of formula II-A. Yield: 26.0g; HPLC purity: 99.0%
  • IR (KBr, cm- 1 ): 3400, 3223, 2944, 1693, 1634, 1560, 1531, 1402, 1239, 1058, 852, 774, 784.
  • Example 2B Preparation of Ethanediamide, V'-fdS, 2R, 4S)-2-amino-4- [(dimethylamino) carbonyl] cyclohexyl]-V 2 -(5-chloro-2-pyridinyl)-, hydrochloride (1:2) (compound of formula II-A)
  • the compound of formula IV (lO.Og) was added to isopropyl alcohol and isopropyl alcohol hydrochloride was then added to it.
  • the reaction mass was heated to about 60°C to 70°C for about 5 hours.
  • the reaction mass was then cooled to about 25°C to 30°C.
  • the reaction mass was then filtered to obtain the product.
  • the product obtained was washed with isopropyl alcohol and dried at about 45°C to 50°C for about 12 hours to get compound of formula II-A. Yield: 70.0g; HPLC purity: 98.0%
  • Example 2C Preparation of Ethanediamide, /V -[(1S, 2R, 4S)-2-amino-4- [(dimethylamino) carbonyl] cyclohexyl]-V 2 -(5-chloro-2-pyridinyl)-, hydrochloride (1:2) (compound of formula II-A)
  • the compound of formula IV (lO.Og) was added to 1, 4-dioxane and concentrated hydrochloric acid was then added to it.
  • the reaction mass was then stirred for about 1 hour at about 25 °C to 30°C.
  • the reaction mass was then diluted with acetone and maintained as it is for about 1 hour.
  • the reaction mass was then filtered to obtain the product and dried at about 45°C to 50°C for about 12 hours to get compound of formula II-A. Yield: 9.3g; HPLC purity: 99.67%
  • Example 2D Preparation of Ethanediamide, ⁇ -[(lS, 2R, 4S)-2-amino-4- [(dimethylamino) carbonyl] cyclohexyl]-/V 2 -(5-chloro-2-pyridinyl)-, hydrochloride (1:2) (compound of formula II)
  • Example 3A Preparation of Ethanediamide, V / - 5-chloro-2-pyridinyl)-V 2 -f(lS, 2R,4S) -4- [(dimethylamino)carbonyl] -2- [ [(4, 5, 6, 7 -tetrahydro-5-methy lthiazolo
  • the compound of formula II-A (50.0g) was added to 1, 4-dioxane and the obtained reaction mass was cooled to about 0°C to 5°C.
  • Triethyl amine (50.0g), 5-Methyl-4, 5, 6, 7-tetrahydrothiazolo [5,4-c]pyridine-2-carboxylic acid hydrochloride (compound of formula III, 34.0g), 1 -hydroxybenzotriazole (HOBt, 20.0g) and l-ethyl-3-(3- dimethylaminopropyl) carbodiimide hydrochloride (EDC.HC1, 35. Og) was added to the reaction mass.
  • the temperature of the reaction mass was then raised to about 25°C to 30°C and the reaction mass was stirred for about 18 hours. Water was added to the reaction mass and the reaction mass was cooled to about 0°C to 5°C. The reaction mass was then filtered to obtain the product (compound of formula I-A). The product obtained was washed with water. The obtained product was then added to dimethyl sulfoxide-water mixture and p-toluene sulfonic acid (17.33g) was added to it and the reaction mass was stirred at about 25 °C to 30°C. The reaction mass was then heated to about 60°C to 70°C to get clear solution. The obtained clear solution was stirred for about 60 min and filtered hot to remove undissolved impurities.
  • Example 3B Preparation of Ethanediamide, / ⁇ - S-chloro ⁇ -pyridiny -ZVAlXlS, 2R,4S) -4- [(dimethylamino)carbonyl] -2- [ [(4, 5, 6, 7 -tetrahydro-5-methy lthiazolo
  • the compound of formula II- A (lO.Og) was added to 1, 4-dioxane and the obtained reaction mass was cooled to about 0°C to 5°C.
  • Triethyl amine (12.42g), 5-Methyl-4, 5,6,7-tetrahydrothiazolo[5, 4-c]pyridine-2-carboxylic acid hydrochloride (compound of formula III, 6.94g), 1-hydroxybenzotriazole (HOBt, 4.0g) and l-ethyl-3-(3- dimethylaminopropyl) carbodiimide hydrochloride (EDC.HC1, 7.1g) was added to the reaction mass.
  • the temperature of the reaction mass was then raised to about 25°C to 30°C and the reaction mass was stirred for about 18 hours. Water was added to the reaction mass and the reaction mass was cooled to about 0°C to 5°C. The reaction mass was then filtered to obtain the product (compound of formula I-A). The obtained product compound of formula I-A was then added to isopropyl alcohol-water mixture and p-toluene sulfonic acid (3.46g) was added to it. The reaction mass was then heated to about 60°C to 70°C to get clear solution. The obtained clear solution was stirred for about 60 min and hot filtered to remove undissolved impurities.
  • Example 3C Preparation of Ethanediamide, /V i -(5-chloro-2-pyridinyl)-/V 2 -[(lS, 2R,4S) -4- [(dimethylamino)carbonyl] -2- [ [(4, 5, 6, 7 -tetrahydro-5-methy lthiazolo
  • Triethyl amine 44.97g
  • 5-Methyl-4, 5, 6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxylic acid hydrochloride compound of formula III, 31.25g
  • 1 -hydroxybenzotriazole HOBt, 18.06g
  • l-ethyl-3-(3- dimethylaminopropyl) carbodiimide hydrochloride EDC.HC1, 32.0g
  • the reaction mass was then filtered to obtain the product (compound of formula I-A).
  • the obtained product, compound of formula I-A was then added to methanol-water mixture and p- toluene sulfonic acid (15.6g) was added to it.
  • the reaction mass was then heated to about 50°C to 60°C to get clear solution.
  • the obtained clear solution was stirred for about 60 minutes and hot filtered to remove undissolved impurities.
  • the filtrate was then cooled to about 25 °C to 30°C and further to about 0°C to 5°C and maintained at same temperature for about 60 minutes.
  • the reaction mass was then filtered to obtain the product.
  • the product obtained was dried at about 50°C to 60°C for about 12 hours to get compound of formula I. Yield: 45.0g, HPLC purity 99.1%.
  • Example 3D Preparation of Ethanediamide, A ⁇ -fS-chloro ⁇ -pyridiny -iV US, 2R,4S) -4- [(dimethylamino)carbonyl] -2- [ [(4, 5, 6, 7 -tetrahydro-5-methy lthiazolo
  • the compound of formula II-A (lO.Og) was added to methylene dichloride and the obtained reaction mass was cooled to about 0°C to 5°C.
  • Triethyl amine 11.16g
  • 5- Methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxylic acid hydrochloride compound of formula III, 6.96g
  • 1 -hydroxybenzotriazole HOBt, 3.67g
  • 1-ethyl- 3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC.HC1, 6.52g) was added to the reaction mass.
  • the temperature of the reaction mass was then raised to about 25°C to 30°C and the reaction mass was stirred for about 18 hours. Water was added to the reaction mass and the reaction mass was stirred and the layers were separated. The organic layer was washed with brine solution. The solvent was distilled out from the organic layer to obtain the product (compound of formula I-A).
  • the obtained product compound of formula I-A was then added to isopropyl alcohol-water mixture and p-toluene sulfonic acid (3.46g) was added to it.
  • the reaction mass was then heated to about 60°C to 70°C to get clear solution. The obtained clear solution was stirred for about 60 min and hot filtered to remove undissolved impurities.
  • the filtrate was then cooled to about 25°C to 30°C and further to about 0°C to 5°C and maintained at same temperature for about 60 minutes.
  • the reaction mass was then filtered to obtain the product.
  • the product obtained was dried at about 50°C to 60°C for about 12 hours to get compound of formula I. Yield: lO.Og, HPLC purity 99.4%.
  • Example 3E Preparation of Edoxaban Free base (compound of formula I-A) directly from Carbamic acid, N-[(1R, 2S, 5S)-2-[[2-[(5-chloro-2-pyridinyl) amino]-2-oxoacetyl] amino] -5- [(dime thy lamino) carbonyl] cyclohexyl]-l, 1- dimethylethyl ester (compound of formula IV):
  • Example 3F the above example may be repeated using EDC. HC1 instead of DCC.
  • Example 4A Recrystallization of Edoxaban tosylate monohydrate
  • the compound of formula I (lO.Og) as obtained in Example 3A-3D was added to isopropyl alcohol-water mixture.
  • the reaction mass was then heated to about 60°C to 70°C and was stirred for about 60 minutes and hot filtered to remove undissolved impurities.
  • the filtrate was then cooled to about 25°C to 30°C for about 60 minutes.
  • the reaction mass was then filtered to obtain the product.
  • the product obtained was washed with isopropyl alcohol, water mixture. Then the product was dried at about 50°C to 60°C for about 12 hours to get compound of formula I. Yield: 9.5g, HPLC purity: 99.67%
  • the compound of formula I (lO.Og) as obtained in Example 3A-3D was added to dimethyl sulfoxide-water mixture.
  • the reaction mass was then heated to about 60°C to 70°C and was stirred for about 60 minutes and hot filtered and washed with dimethyl sulfoxide.
  • the filtrate was again heated to 70°C and stirred for about 30 minutes and then cooled to 50°C and stirred for 120 min. It was further cooled to about 0°C-5°C and stirred for 60 min.
  • the product was filtered, wet cake was washed with water and dried at about 50°C to 60°C for 12.0 hours to get edoxaban tosylate monohydrate; yield 9.5g, HPLC purity 99.14%.
  • Example 3A-3D The compound of formula I (lO.Og) as obtained in Example 3A-3D was added to methanol-water mixture. The reaction mass was then heated to about 60°C to 65°C and was stirred for about 60 minutes and hot filtered and washed with dimethyl sulfoxide. The filtrate was cooled to about 25°C-30°C and further to about 0°C -5°C and stirred for 60 min. The product was filtered, wet cake was washed with water and dried at about 50°C to 60°C for 12.0 hours to get edoxaban tosylate monohydrate; yield 9.0g, HPLC purity 99.18%.
  • Example 3A-3D The compound of formula I (13.0g) as obtained in Example 3A-3D was added to acetone (97.5 mL), water (97.5 mL) mixture. The reaction mass was then heated to about 50°C to 55°C and was stirred for about 30 minutes and filtered hot and washed with acetone and water mixture. The filtrate was cooled to about 25°C-30°C and further to about 5°C to 10°C and stirred for 120 min. The product was filtered, wet cake was washed with water and dried at about 45°C to 50°C for 12.0 hours to get edoxaban tosylate monohydrate; yield 11.20g (86.0%), HPLC purity: 99.91 %
  • Example 4E Preparation of Ethanediamide, /V i -(5-chloro-2-pyridinyl)-/V 2 -[(lS, 2R,4S) -4- [(dimethylamino)carbonyl] -2- [ [(4, 5, 6, 7 -tetrahydro-5-methy lthiazolo
  • the compound of formula I-A (20.0g) as obtained in Example 3E -3F was added to acetone (125 mL), water (125 mL) mixture and p-toluene sulfonic acid 8.30g) was added to it and flushed with 50% aq. (50 mL).
  • the reaction mass was then heated to about 50°C to 60°C to get clear solution.
  • the obtained clear solution was stirred for about 60 min and hot filtered and washed with acetone and water mixture.
  • the filtrate was then cooled to about 5°C to 10°C and maintained at same temperature for about 240 minutes.
  • the reaction mass was then filtered and dried at about 45°C to 50°C for about 12 hours to get compound of formula I. Yield: 22.0g (82.0%), HPLC purity 99.94%
  • the reaction mass was then stirred at about 55°C to 60°C for about 18 hours.
  • the reaction mass was then cooled to about 25 °C to 30°C.
  • Water was then added to the reaction mass under stirring and the reaction mass was stirred for 60 minutes.
  • the reaction mass was then filtered to obtain the product.
  • the product obtained was dried at about 45 °C to 50°C to obtain the compound of formula IV. Yield: 5g.
  • the reaction mass was then stirred at about 55°C to 60°C for about 10 hours.
  • the reaction mass was then cooled to about 25°C to 30°C. Water was then added to the reaction mass under stirring and the reaction mass was stirred for 60 minutes.
  • the reaction mass was then filtered to obtain the product.
  • the product obtained was dried at about 45 °C to 50°C for about 12 hours to obtain the compound of formula IV. Yield: 7g.
  • reaction mass was then stirred at about 55°C to 60°C for about 6 hours.
  • the reaction mass was then cooled to about 25°C to 30°C for about 12 hours.
  • Water was then added to the reaction mass under stirring and the reaction mass was further cooled to about 0°C to 5°C and stirred for 120 minutes.
  • the reaction mass was then filtered to obtain the product.
  • the product obtained was washed with water and dried at about 45 °C to 50°C for about 12 hours to obtain the compound of formula IV. Yield: 24.0g.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

The present invention relates to process for preparation N1-(5-Chloropyridin-2-yl)-N2-[(1S,2R,4S)-4-(N,N-dimethylcarbamoyl)-2-(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-ylcarboxamido)cyclohexyl]oxamide p-toluene sulfonate monohydrate [edoxaban tosylate monohydrate], the compound of formula (I), comprising reacting compound of formula (VI) with compound of formula (V) to obtain the compound of formula (IV) and further converting it to edoxaban tosylate monohydrate in an industrially feasible process.

Description

PROCESS FOR PREPARATION OF EDOXABAN
PRIORITY
[0001] This application claims the benefit of Indian Provisional Application 201921026759 filed on July 4, 2019, entitled“PROCESS FOR PREPARATION OF EDOXABAN”, the contents of which are incorporated herein by reference.
FIELD OF THE INVENTION
[0002] The present invention relates to a process for the preparation of edoxaban and salts thereof.
BACKGROUND OF THE INVENTION
[0003] Savaysa (Edoxaban tosylate monohydrate) is /V-(5-chloropyridin-2-yl)-/V'- [(lS,2R,4S)-4 (/V,/V-dimethyl carbamoyl)- 2-(5-methyl-4,5,6,7-tetrahydro [1,3] thiazolo[5,4-c]pyridine-2-carboxamido)cyclohexyl]oxamide mono(4-methyl benzenesulfonate) monohydrate depicted by compound of formula I.
Figure imgf000003_0001
[0004] Savaysa is a factor Xa inhibitor, indicated to reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF). Savaysa is available as 15 mg, 30 mg and 60 mg oral tablets.
[0005] The present invention provides a simple and industrially advantageous process for preparing edoxaban. In the preparation of edoxaban, compound of Formula IV is an important intermediate, prepared by the reaction of compound of formula V with a compound of formula VI.
Figure imgf000004_0001
[0006] This reaction requires use of a base and it has been observed that when a base is added to the compound of formula V, and when acetonitrile is used as a solvent there is formation of a gel which gets deposited and consequently the reaction system hardens and solidifies making stirring difficult and reducing the yield and purity of compound of formula IV. To circumvent this problem, the compound of formula VI is treated with one portion of a base and then the compound of formula V is added followed by addition of another portion of the base. Thus a particular sequence of addition of the two reactants compound V and VI and adding the base in divided portions is required to solve the problem of the reaction system solidifying.
[0007] Surprisingly it has been found that by the process of the present invention, wherein dimethyl sulfoxide is used as a solvent in the reaction of compound of formula V with a compound of formula VI in presence of a base, the problem of gel formation and reaction system hardening is circumvented, leading to the formation of compound of formula II in high yields and purity. The use of dimethylsulfoxide as a solvent does not require a particular sequence of addition of reactants or use of base in divided portions and provides reaction simplicity and also ensures the completion of reaction in lesser time.
SUMMARY OF THE INVENTION
[0008] The present invention provides a process for the preparation of edoxaban tosylate monohydrate, a compound of formula I, comprising: a) reacting the compound of formula V with a compound of formula VI in the presence of a base and a solvent to obtain compound of formula IV, wherein the solvent is dimethyl sulfoxide;
Figure imgf000005_0001
b) reacting the compound of formula IV with a deprotecting reagent to obtain a compound of formula II or salt thereof;
Figure imgf000005_0002
c) reacting the compound of formula II or salt thereof with compound of formula III in the presence of a base to obtain a compound of formula I-A;
Figure imgf000005_0003
d) reacting the compound of formula I-A with para toluene sulfonic acid in a solvent to obtain a compound of formula I; and e) optionally, recrystallizing the compound of formula I with a solvent.
BRIEF DESCRIPTION OF THE DRAWINGS
[0009] Fig. 1: XRD pattern of edoxaban tosylate monohydrate as obtained from example 4E.
[0010] Fig 2: XRD pattern of edoxaban free base as obtained from example 3E.
DETAILED DESCRIPTION OF THE INVENTION
[0011] The present invention provides a process for the preparation of edoxaban tosylate monohydrate, a compound of formula I, comprising:
a) reacting a compound of formula V with a compound of formula VI in the presence of a base and a solvent to obtain a compound of formula IV, wherein the solvent is dimethyl sulfoxide;
Figure imgf000006_0001
b) reacting the compound of formula IV obtained in step a) with a deprotecting reagent to obtain a compound of formula II or salt thereof;
Figure imgf000006_0002
II c) reacting the compound of formula II or salt thereof obtained in step b) with a compound of formula III in the presence of a base to obtain a compound of formula I- A;
Figure imgf000007_0001
d) reacting compound of formula I-A obtained in step c) with para toluene sulfonic acid in a solvent to obtain compound of formula I; and
e) optionally, recrystallizing the compound of formula I with solvent.
[0012] In one embodiment, in step a) the base is added in one lot.
[0013] The addition of base in one lot means the entire amount of base is added all at once in a single portion and is not added in parts.
[0014] In one embodiment, in step a) the base is an amine and/or nitrogen- containing heterocyclic compounds.
[0015] In one embodiment, in step a) the base is selected from the group consisting of triethyl amine, pyridine, alkane amines, such as methylamine, diisopropylamine; imidazole, benzimidazole, histidine, guanidine phosphazene, n-methyl morpholine, morpholine, n-methylpyrolidine and the like.
[0016] In one embodiment, in step a), the base is triethyl amine.
[0017] In one embodiment, the base used in step a) is added in one lot.
[0018] In one embodiment, in step a), the base, triethyl amine is not added in parts.
[0019] In one embodiment in step a), the reaction is carried out at a temperature in the range of 40 -80°C.
[0020] In one embodiment in step a), the reaction is carried out for a period of 1- 10 hours. [0021] In one embodiment in step a), the reaction is carried out at a temperature in the range of 50 -60°C for about 2-8 hours.
[0022] In one embodiment compound of formula IV is obtained in at least 90% yield with respect to compound of formula V.
[0023] In one embodiment compound of formula IV is obtained in a purity of at least
99%w/w as determined by HPLC.
[0024] In one embodiment, in step b) the deprotecting reagent is selected from ethyl acetate hydrochloride, hydrochloric acid, isopropyl alcohol HC1, methyl alcohol HC1, 1,4-dioxane HC1, ethanol HC1, isopropyl ether HC1, n-propanol HC1 and the like.
[0025] In one embodiment, in step b) the deprotecting agent is hydrochloric acid.
[0026] In one embodiment, in step b) the deprotection is carried out in a solvent selected from the group consisting of ethyl acetate, acetone, isopropyl alcohol, dioxane, methanol, dimethyl sulfoxide, tetrahydrofuran, toluene, xylene, methylene dichloride, dimethyl formamide and the like.
[0027] In one embodiment, the deprotecting agent used in step b) is selected from the group consisting of ethyl acetate hydrochloride in ethyl acetate solvent, hydrochloric acid in dioxane solvent and hydrochloric acid in acetone solvent.
[0028] In embodiment, in step b) the deprotection is carried out using hydrochloric acid in acetone solvent.
[0029] In one embodiment, in step b) the compound of formula II obtained in step b) is a dihydrochloride salt, a compound of formula II-A
Figure imgf000008_0001
IIA [0030] In one embodiment, in step c), the reaction may be carried out in presence of a solvent selected from the group consisting of dioxane, methylene dichloride, ethyl acetate, dimethyl formamide, tetrahydrofuran, dimethyl sulfoxide.
[0031] In one embodiment, in step c) the reaction is carried out in presence of methylene dichloride solvent.
[0032] In one embodiment, in step c) the base is an amine and/or nitrogen- containing heterocyclic compounds.
[0033] In one embodiment, in step c) the base is selected from the group consisting of triethyl amine, diisopropylethyl amine, pyridine, alkane amines, such as methylamine, diisopropylamine, imidazole, benzimidazole, histidine, guanidine phosphazene bases, n-methyl morpholine, morpholine, n-methylpyrolidine and the like.
[0034] In one embodiment, the base is either triethyl amine or diisopropyl amine.
[0035] In one embodiment, in step c) an activating agent may be used.
[0036] In one embodiment, the activating agent may be selected from the group consisting of carbodiimides; 1- hydroxybenzotriazole based or l-hydroxy-7- azabenzotriazole based phosphonium and uronium salts; halouronium and halophosphonium salts; benzotriazine based uronium salts and phosphates; N- acylimidazoles; N-acyltriazoles and the like.
[0037] In one embodiment, the carbodiimide activating agent may be selected from the group consisting of N, N’-dialkylcarbodiimides such as N, N’- dicyclohexylcarbodiimide (DCC) or diisopropylcarbodiimide (DIPC), l-ethyl-3-(3- dimethylaminopropyl)-carbodiimide (EDC) and the like.
[0038] In one embodiment, 1 -hydroxybenzotriazole and l-hydroxy-7-azabenzotriazole based phosphonium salt may be selected from the group consisting of benzotriazol-1- yl-N-oxy-tris(dimethylamino)phosphonium hexafluorophosphate (BOP), benzotriazol- 1 -yl-N-oxy-tris(pyrrolidino)phosphonium hexafluorophosphate
(PyBOP), 7-azabenzotriazol-l-yl-N-oxy-tris(pyrrolidino)phosphonium hexafluorophosphate (PyAOP) and the like. [0039] In one embodiment, in step c) the coupling agent is N, N’- dicyclohexylcarbodiimide (DCC) or EDC.HC1
[0040] In one embodiment, in step c) an additive may be used.
[0041] In one embodiment, the additive may be selected from the group consisting of 1 -hydroxybenzotriazole (HOBt), l-hydroxy-7-azabenzotriazole (HOAt), 3,4-dihydro-
3-hydroxy-4-oxo-l,2,3-benzotriazine (DHOBt) and the like.
[0042] In one embodiment, step c) is carried out in presence of dicyclohexylcarbodiimide (DCC) and 1 -hydroxybenzotriazole (HOBt).
[0043] In one embodiment, the compound of formula I-A may be optionally purified by solvent selected from the group consisting of methanol, ethanol, isopropyl alcohol and n-butanol, water or mixtures thereof.
[0044] In one embodiment, in step d) the compound of formula I-A and para toluene sulfonic acid is suspended in a solvent selected from the group consisting of acetone, dimethyl sulfoxide, isopropyl alcohol, methanol, ethanol, water or mixture thereof.
[0045] In one embodiment, in step d) the amount of para toluene sulfonic acid added is 1.27 -1.3 molar equivalent with respect to edoxaban, a compound of formula I-A.
[0046] In one embodiment, in step d) the para toluene sulfonic acid is added in one lot.
[0047] In one embodiment, in step d) the compound of formula I-A and para toluene sulfonic acid are suspended in a solvent and heated to about 40°C to about 70°C.
[0048] In one embodiment, in step d) the compound of formula I-A and para toluene sulfonic acid is suspended in a solvent and heated to about 55°C to about 65°C for a period of about 1-2 hours, followed by filtration.
[0049] In one embodiment, the filtrate is cooled to obtain the compound of formula I.
[0050] In one embodiment, no water is added to the filtrate to obtain the compound of formula I.
[0051] In one embodiment, in step e) the recrystallization of compound of formula I is carried out in a solvent selected from the group consisting of acetone, dimethyl sulfoxide, isopropyl alcohol, methanol, water or mixture thereof. [0052] In one embodiment, the present invention provides a process for the preparation of edoxaban tosylate monohydrate, a compound of formula I comprising:
a) reacting a compound of formula V with a compound of formula VI in the presence of triethyl amine and dimethyl sulfoxide to obtain a compound of formula IV ;
b) reacting the compound of formula IV with ethyl acetate hydrochloride or hydrochloric acid to obtain a compound of formula II-A;
c) reacting the compound of formula II-A with a compound of formula III in the presence of a base to obtain compound of formula I-A;
d) reacting the compound of formula I-A with para toluene sulfonic acid in a solvent to obtain compound of formula I; and
e) optionally, recrystallizing the compound of formula I with a solvent.
[0053] In one embodiment, the present invention provides a process for the preparation of edoxaban tosylate monohydrate, a compound of formula I comprising:
a) reacting a compound of formula V with a compound of formula VI in the presence of triethyl amine and dimethyl sulfoxide to obtain a compound of formula IV;
b) reacting the compound of formula IV with hydrochloric acid in acetone to obtain a compound of formula II-A;
c) reacting the compound of formula II-A with a compound of formula III in the presence of a base to obtain compound of formula I-A;
d) reacting the compound of formula I-A with para toluene sulfonic acid in a solvent to obtain compound of formula I; and
e) optionally, recrystallizing the compound of formula I with a solvent.
[0054] In one embodiment, the present invention provides a process for the preparation of edoxaban tosylate monohydrate, a compound of formula I comprising:
a) reacting a compound of formula V with a compound of formula VI in the presence of base and a non-nitrile solvent to obtain compound of formula IV ;
b) reacting the compound of formula IV, with a deprotecting reagent to obtain compound of formula II or salt thereof; c) reacting compound of formula II or salt thereof with compound of formula III in the presence of a base to obtain compound of formula I-A;
d) reacting compound of formula I-A with para toluene sulfonic acid in a solvent to obtain compound of formula I; and
e) optionally, recrystallization of compound of formula I with solvent.
[0055] In one embodiment, in step a) the non-nitrile solvent is selected from the group consisting of acetone, dioxane, isopropyl alcohol, tetrahydrofuran, toluene, dimethylformamide, dimethyl acetamide, dimethyl sulfoxide.
[0056] In one embodiment, the present invention provides a compound of formula II- A
Figure imgf000012_0001
II-A
characterized by 1H NMR (400MHz, dimethyl sulfoxide, d6): 1.35-1.44, 1.65-1.78,
2.01-2.10, 2.76, 3.04, 3.32, 3.71, 3.85, 7.68, 7.98-8.05, 8.42-8.45, 8.94, 10.34.
[0057] In one embodiment, the present invention provides a process for the preparation of compound of formula II-A comprising:
a) reacting a compound of formula V with a compound of formula VI in the presence of a base and a solvent to obtain a compound of formula IV, wherein the solvent is dimethyl sulfoxide; and
b) reacting the compound of formula IV with ethyl acetate hydrochloride or hydrochloric acid to obtain a compound of formula II-A.
[0058] In one embodiment, the present invention provides a process for the preparation of compound of formula II-A comprising: a) reacting a compound of formula V with a compound of formula VI in the presence of a base and a solvent to obtain a compound of formula IV, wherein the solvent is dimethyl sulfoxide; and
b) reacting the compound of formula IV with acetone and hydrochloric acid to obtain a compound of formula II-A.
HPLC method: High performance liquid chromatography (HPLC) was performed with the conditions described below for detecting purity:
Column: Inertsil ODS 3V 250 X 4.6mm, 5m, Column temperature: 30°C, Mobile phase: A = Buffer (100%), B = Methanol: Acetonitrile (60:40, v/v), Diluent: Water: Acetonitrile (90: 10 v/v); Flow Rate: 1.0 mL/minute, Detection wavelength: UV 230 nm, Injection volume: 20 pL, Buffer: 0.1% Perchloric acid in water.
[0059] The examples that follow are provided to enable one skilled in the art to practice the invention and are merely illustrative of the invention. The examples should not be read as limiting the scope of the invention.
Examples
Example 1A: Preparation of carbamic acid, N-[(1R, 2S, 5S)-2-[[2-[(5-chloro-2- pyridinyl) amino]-2-oxoacetyl] amino] -5- [(dime thy lamino) carbonyl] cyclohexyl]- 1, 1-dimethylethyl ester (compound of formula IV):
To a solution of t-Butyl {(1R, 2S, 5S)-2-amino-5 [(dimethylamino) carbonyl] cyclohexyl} carbamate oxalate (compound of formula V, 15g) in dimethyl sulfoxide, triethyl amine (18.5g) was added and the reaction mass was heated to about 50°C to 55°C. Ethyl 2-((chloropyridin-2-yl) amino)-2-oxoacetate hydrochloride (compound of formula VI, 12.7g) was to the reaction mass. The reaction mass was then stirred at about 55 °C to 60°C for about 2 to about 6 hours. The reaction mass was then cooled to about 25°C to 30°C. Water was then added to the reaction mass under stirring and the reaction mass was further cooled to about 0°C to 5°C and stirred for 120 minutes. The reaction mass was then filtered to obtain the product. The product obtained was washed with water and dried at about 45°C to 50°C for about 12 hours to obtain the compound of formula IV. Yield: 18g.
Example IB: Preparation of carbamic acid, N-[(1R, 2S, 5S)-2-[[2-[(5-chloro-2- pyridinyl) amino]-2-oxoacetyl] amino] -5- [(dime thy lamino) carbonyl] cyclohexyl]- 1, 1-dimethylethyl ester (compound of formula IV):
To a solution of t-Butyl {(1R, 2S, 5S)-2-amino-5 [(dimethylamino) carbonyl] cyclohexyl} carbamate oxalate (compound of formula V, lOg) in dimethyl sulfoxide (50mL), triethyl amine (13.46g) was added and the reaction mass was heated to about 55°C to 60°C. Ethyl 2-((chloropyridin-2-yl) amino)-2-oxoacetate hydrochloride (compound of formula VI, 7.77g), was then added to the reaction mass and flushed with DMSO (lOmL). The reaction mass was then stirred at about 55°C to 60°C for about 5 hours, cooled to about 25°C to 30°C and stirred for about 12 hrs. After completion, water was added to the reaction mass under stirring and stirred for 180 minutes. Filtered the product, washed with water and dried at about 45°C to 50°C for about 12 hours to obtain the compound of formula IV. Yield: 11.10g (89.5%); HPLC purity: 99.55% Example 2A: Preparation of Ethanediamide, ^-[(lS, 2R, 4S)-2-amino-4- [(dimethylamino) carbonyl] cyclohexyl]-/V2-(5-chloro-2-pyridinyl)-, hydrochloride (1:2) (compound of formula II -A)
The compound of formula IV (28.0g) was added to ethyl acetate and ethyl acetate hydrochloride (8-10%) was then added to it. The reaction mass was heated to about 60°C to 70°C for about 3 hours. The reaction mass was then cooled to about 25°C to 30°C. The reaction mass was then filtered to obtain the product. The product obtained was washed with ethyl acetate and dried at about 45°C to 50°C for about 12 hours to get compound of formula II-A. Yield: 26.0g; HPLC purity: 99.0%
IR (KBr, cm-1): 3400, 3223, 2944, 1693, 1634, 1560, 1531, 1402, 1239, 1058, 852, 774, 784.
1H-NMR (400MHz, dimethyl sulfoxide, d6): 1.35-1.44, 1.65-1.78, 2.01-2.10, 2.76, 3.04, 3.32, 3.71, 3.85, 7.68, 7.98-8.05, 8.42-8.45, 8.94, 10.34.
Example 2B: Preparation of Ethanediamide, V'-fdS, 2R, 4S)-2-amino-4- [(dimethylamino) carbonyl] cyclohexyl]-V2-(5-chloro-2-pyridinyl)-, hydrochloride (1:2) (compound of formula II-A)
The compound of formula IV (lO.Og) was added to isopropyl alcohol and isopropyl alcohol hydrochloride was then added to it. The reaction mass was heated to about 60°C to 70°C for about 5 hours. The reaction mass was then cooled to about 25°C to 30°C. The reaction mass was then filtered to obtain the product. The product obtained was washed with isopropyl alcohol and dried at about 45°C to 50°C for about 12 hours to get compound of formula II-A. Yield: 70.0g; HPLC purity: 98.0%
Example 2C: Preparation of Ethanediamide, /V -[(1S, 2R, 4S)-2-amino-4- [(dimethylamino) carbonyl] cyclohexyl]-V2-(5-chloro-2-pyridinyl)-, hydrochloride (1:2) (compound of formula II-A)
The compound of formula IV (lO.Og) was added to 1, 4-dioxane and concentrated hydrochloric acid was then added to it. The reaction mass was then stirred for about 1 hour at about 25 °C to 30°C. The reaction mass was then diluted with acetone and maintained as it is for about 1 hour. The reaction mass was then filtered to obtain the product and dried at about 45°C to 50°C for about 12 hours to get compound of formula II-A. Yield: 9.3g; HPLC purity: 99.67%
Example 2D: Preparation of Ethanediamide, ^-[(lS, 2R, 4S)-2-amino-4- [(dimethylamino) carbonyl] cyclohexyl]-/V2-(5-chloro-2-pyridinyl)-, hydrochloride (1:2) (compound of formula II)
The compound of formula IV (20.0g) as obtained from example IB was added to acetone (200mL) and concentrated hydrochloric acid (40 mL) was then added to it. The reaction mass was then stirred for about 2 hours at about 25°C to 30°C. After completion reaction mass was filtered and dried at about 45°C to 50°C in vacuum tray dryer for about 6-7 hours to get compound of formula II-A. Yield: 18.40g (97.66%); HPLC purity: 99.61 %
Example 3A: Preparation of Ethanediamide, V/- 5-chloro-2-pyridinyl)-V2-f(lS, 2R,4S) -4- [(dimethylamino)carbonyl] -2- [ [(4, 5, 6, 7 -tetrahydro-5-methy lthiazolo
[5,4,c]pyridin-2-yl)carbonyl]amino]cylohexyl]-,4-methylbenzenesulfonate, hydrate (1:1:1) (compound of formula I)
The compound of formula II-A (50.0g) was added to 1, 4-dioxane and the obtained reaction mass was cooled to about 0°C to 5°C. Triethyl amine (50.0g), 5-Methyl-4, 5, 6, 7-tetrahydrothiazolo [5,4-c]pyridine-2-carboxylic acid hydrochloride (compound of formula III, 34.0g), 1 -hydroxybenzotriazole (HOBt, 20.0g) and l-ethyl-3-(3- dimethylaminopropyl) carbodiimide hydrochloride (EDC.HC1, 35. Og) was added to the reaction mass. The temperature of the reaction mass was then raised to about 25°C to 30°C and the reaction mass was stirred for about 18 hours. Water was added to the reaction mass and the reaction mass was cooled to about 0°C to 5°C. The reaction mass was then filtered to obtain the product (compound of formula I-A). The product obtained was washed with water. The obtained product was then added to dimethyl sulfoxide-water mixture and p-toluene sulfonic acid (17.33g) was added to it and the reaction mass was stirred at about 25 °C to 30°C. The reaction mass was then heated to about 60°C to 70°C to get clear solution. The obtained clear solution was stirred for about 60 min and filtered hot to remove undissolved impurities. The filtrate was then cooled to about 25°C to 30°C and further to about 0°C to 5°C and maintained at same temperature for about 60 min. The reaction mass was then filtered to obtain the product. The product obtained dried at about 50°C to 60°C for about 12 hours to get compound of formula I. Yield: lOO.Og, HPLC purity: 99.25%
Example 3B: Preparation of Ethanediamide, /^- S-chloro^-pyridiny -ZVAlXlS, 2R,4S) -4- [(dimethylamino)carbonyl] -2- [ [(4, 5, 6, 7 -tetrahydro-5-methy lthiazolo
[5,4,c]pyridin-2-yl)carbonyl]amino]cylohexyl]-4-methyl benzenesulfonate, hydrate (1:1:1) (compound of formula I)
The compound of formula II- A (lO.Og) was added to 1, 4-dioxane and the obtained reaction mass was cooled to about 0°C to 5°C. Triethyl amine (12.42g), 5-Methyl-4, 5,6,7-tetrahydrothiazolo[5, 4-c]pyridine-2-carboxylic acid hydrochloride (compound of formula III, 6.94g), 1-hydroxybenzotriazole (HOBt, 4.0g) and l-ethyl-3-(3- dimethylaminopropyl) carbodiimide hydrochloride (EDC.HC1, 7.1g) was added to the reaction mass. The temperature of the reaction mass was then raised to about 25°C to 30°C and the reaction mass was stirred for about 18 hours. Water was added to the reaction mass and the reaction mass was cooled to about 0°C to 5°C. The reaction mass was then filtered to obtain the product (compound of formula I-A). The obtained product compound of formula I-A was then added to isopropyl alcohol-water mixture and p-toluene sulfonic acid (3.46g) was added to it. The reaction mass was then heated to about 60°C to 70°C to get clear solution. The obtained clear solution was stirred for about 60 min and hot filtered to remove undissolved impurities. The filtrate was then cooled to about 25°C to 30°C and further to about 0°C to 5°C and maintained at same temperature for about 60 minutes. The reaction mass was then filtered to obtain the product. The product obtained was dried at about 50°C to 60°C for about 12 hours to get compound of formula I. Yield: 60%, HPLC purity: 99.25%
Example 3C: Preparation of Ethanediamide, /Vi-(5-chloro-2-pyridinyl)-/V2-[(lS, 2R,4S) -4- [(dimethylamino)carbonyl] -2- [ [(4, 5, 6, 7 -tetrahydro-5-methy lthiazolo
[5,4,c]pyridin-2-yl)carbonyl]amino]cylohexyl]-4-methylbenzenesulfonate, hydrate (1:1:1) (compound of formula I) The compound of formula II- A (45. Og) was added to 1, 4-dioxane and the obtained reaction mass was cooled to about 0°C to 5°C. Triethyl amine (44.97g), 5-Methyl-4, 5, 6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxylic acid hydrochloride (compound of formula III, 31.25g), 1 -hydroxybenzotriazole (HOBt, 18.06g) and l-ethyl-3-(3- dimethylaminopropyl) carbodiimide hydrochloride (EDC.HC1, 32.0g) was added to the reaction mass. The temperature of the reaction mass was then raised to about 25°C to 30°C and the reaction mass was stirred for about 18 hours. Water was added to the reaction mass and the reaction mass was cooled to about 0°C to 5°C. The reaction mass was then filtered to obtain the product (compound of formula I-A). The obtained product, compound of formula I-A was then added to methanol-water mixture and p- toluene sulfonic acid (15.6g) was added to it. The reaction mass was then heated to about 50°C to 60°C to get clear solution. The obtained clear solution was stirred for about 60 minutes and hot filtered to remove undissolved impurities. The filtrate was then cooled to about 25 °C to 30°C and further to about 0°C to 5°C and maintained at same temperature for about 60 minutes. The reaction mass was then filtered to obtain the product. The product obtained was dried at about 50°C to 60°C for about 12 hours to get compound of formula I. Yield: 45.0g, HPLC purity 99.1%.
Example 3D: Preparation of Ethanediamide, A^-fS-chloro^-pyridiny -iV US, 2R,4S) -4- [(dimethylamino)carbonyl] -2- [ [(4, 5, 6, 7 -tetrahydro-5-methy lthiazolo
[5,4,c]pyridin-2-yl)carbonyl]amino]cylohexyl]-4-methylbenzenesulfonate, hydrate (1:1:1) (compound of formula I)
The compound of formula II-A (lO.Og) was added to methylene dichloride and the obtained reaction mass was cooled to about 0°C to 5°C. Triethyl amine (11.16g), 5- Methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxylic acid hydrochloride (compound of formula III, 6.96g), 1 -hydroxybenzotriazole (HOBt, 3.67g) and 1-ethyl- 3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC.HC1, 6.52g) was added to the reaction mass. The temperature of the reaction mass was then raised to about 25°C to 30°C and the reaction mass was stirred for about 18 hours. Water was added to the reaction mass and the reaction mass was stirred and the layers were separated. The organic layer was washed with brine solution. The solvent was distilled out from the organic layer to obtain the product (compound of formula I-A). The obtained product compound of formula I-A was then added to isopropyl alcohol-water mixture and p-toluene sulfonic acid (3.46g) was added to it. The reaction mass was then heated to about 60°C to 70°C to get clear solution. The obtained clear solution was stirred for about 60 min and hot filtered to remove undissolved impurities. The filtrate was then cooled to about 25°C to 30°C and further to about 0°C to 5°C and maintained at same temperature for about 60 minutes. The reaction mass was then filtered to obtain the product. The product obtained was dried at about 50°C to 60°C for about 12 hours to get compound of formula I. Yield: lO.Og, HPLC purity 99.4%.
Example 3E: Preparation of Edoxaban Free base (compound of formula I-A) directly from Carbamic acid, N-[(1R, 2S, 5S)-2-[[2-[(5-chloro-2-pyridinyl) amino]-2-oxoacetyl] amino] -5- [(dime thy lamino) carbonyl] cyclohexyl]-l, 1- dimethylethyl ester (compound of formula IV):
The compound of formula IV (25.0g) obtained from example IB was added to acetone
(250 mL) and concentrated hydrochloric acid (50 mL) was then added to it. The reaction mass was then stirred for about 2 hours at about 25°C to 30°C. After completion of the reaction mass, filtered the slurry mass, washed with acetone and suck dried. The obtained wet cake was suspended in methylene dichloride (250 mL) and added 5-Methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxylic acid hydrochloride (compound of formula III, 15.05g, diisopropyl ethyl amine (34.5g), N,N- dicyclohexyl carbodiimide (DCC) ( 16.5 lg) and 1-hydroxybenzotriazole (HOBt, 3.62g). The reaction mass was heated to about 35°C to 40°C for about 5 hours. After completion ,the reaction mass was cooled to about 0°C to 5°C for about 1 hour, filtered. The combined filtrate was washed with 5% aq. NaHCCL followed by brine solution. The solvent was distilled to obtain the crude product (compound of formula I-A) to which methanol (200 mL) was added and heated to 60°C to 65 °C for about 1 hour then cooled to 25 °C to 30°C for 1 hour, filtered, washed with methanol to obtained wet cake which was dried in tray drier at 40°C to 45 °C to obtain compound of formula I- A (24.90g, 85.13%), HPLC purity 99.47.
XRPD table for edoxaban free base, compound of formula I-A:
Figure imgf000020_0001
Example 3F: the above example may be repeated using EDC. HC1 instead of DCC. Example 4A: Recrystallization of Edoxaban tosylate monohydrate
The compound of formula I (lO.Og) as obtained in Example 3A-3D was added to isopropyl alcohol-water mixture. The reaction mass was then heated to about 60°C to 70°C and was stirred for about 60 minutes and hot filtered to remove undissolved impurities. The filtrate was then cooled to about 25°C to 30°C for about 60 minutes. The reaction mass was then filtered to obtain the product. The product obtained was washed with isopropyl alcohol, water mixture. Then the product was dried at about 50°C to 60°C for about 12 hours to get compound of formula I. Yield: 9.5g, HPLC purity: 99.67%
Example 4B: Recrystallization of Edoxaban tosylate monohydrate
The compound of formula I (lO.Og) as obtained in Example 3A-3D was added to dimethyl sulfoxide-water mixture. The reaction mass was then heated to about 60°C to 70°C and was stirred for about 60 minutes and hot filtered and washed with dimethyl sulfoxide. The filtrate was again heated to 70°C and stirred for about 30 minutes and then cooled to 50°C and stirred for 120 min. It was further cooled to about 0°C-5°C and stirred for 60 min. The product was filtered, wet cake was washed with water and dried at about 50°C to 60°C for 12.0 hours to get edoxaban tosylate monohydrate; yield 9.5g, HPLC purity 99.14%.
Example 4C: Recrystallization of Edoxaban tosylate monohydrate
The compound of formula I (lO.Og) as obtained in Example 3A-3D was added to methanol-water mixture. The reaction mass was then heated to about 60°C to 65°C and was stirred for about 60 minutes and hot filtered and washed with dimethyl sulfoxide. The filtrate was cooled to about 25°C-30°C and further to about 0°C -5°C and stirred for 60 min. The product was filtered, wet cake was washed with water and dried at about 50°C to 60°C for 12.0 hours to get edoxaban tosylate monohydrate; yield 9.0g, HPLC purity 99.18%.
Example 4D: Recrystallization of Edoxaban tosylate monohydrate
The compound of formula I (13.0g) as obtained in Example 3A-3D was added to acetone (97.5 mL), water (97.5 mL) mixture. The reaction mass was then heated to about 50°C to 55°C and was stirred for about 30 minutes and filtered hot and washed with acetone and water mixture. The filtrate was cooled to about 25°C-30°C and further to about 5°C to 10°C and stirred for 120 min. The product was filtered, wet cake was washed with water and dried at about 45°C to 50°C for 12.0 hours to get edoxaban tosylate monohydrate; yield 11.20g (86.0%), HPLC purity: 99.91 %
Example 4E: Preparation of Ethanediamide, /Vi-(5-chloro-2-pyridinyl)-/V2-[(lS, 2R,4S) -4- [(dimethylamino)carbonyl] -2- [ [(4, 5, 6, 7 -tetrahydro-5-methy lthiazolo
[5, 4, c]-pyridin-2-yl)carbonyl]amino]cylohexyl]-, 4-methyl benzene sulfonate, hydrate (1:1:1) (compound of formula I)
The compound of formula I-A (20.0g) as obtained in Example 3E -3F was added to acetone (125 mL), water (125 mL) mixture and p-toluene sulfonic acid 8.30g) was added to it and flushed with 50% aq. (50 mL). The reaction mass was then heated to about 50°C to 60°C to get clear solution. The obtained clear solution was stirred for about 60 min and hot filtered and washed with acetone and water mixture. The filtrate was then cooled to about 5°C to 10°C and maintained at same temperature for about 240 minutes. The reaction mass was then filtered and dried at about 45°C to 50°C for about 12 hours to get compound of formula I. Yield: 22.0g (82.0%), HPLC purity 99.94%
XRPD table for edoxaban tosylate monohydrate, compound of formula I:
Figure imgf000022_0002
Example 5: Preparation of Carbamic acid,
Figure imgf000022_0001
2S, 5S)-2-[[2-[(5-chloro-2- pyridinyl)amino]-2-oxoacetyl] amino]-5-[(dimethylamino) carbonyl] cyclohexyl]-
1,1-dimethylethyl ester (compound of formula IV)
To a solution of t-Butyl {(1R, 2S, 5S)-2-amino-5 [(dimethylamino) carbonyl] cyclohexyl) carbamate oxalate (compound of formula V, lO.Og) in 1,4-dioxane, triethyl amine (12.35g) was added and the reaction mass was heated to about 50°C to 55°C. At this stage the reaction mass thicken due to gel deposition and stirring becomes difficult. Ethyl 2-((chloropyridin-2-yl) amino)-2-oxoacetate hydrochloride (compound of formula VI, 8.47g) was then added to the reaction mass. The reaction mass was then stirred at about 55°C to 60°C for about 18 hours. The reaction mass was then cooled to about 25 °C to 30°C. Water was then added to the reaction mass under stirring and the reaction mass was stirred for 60 minutes. The reaction mass was then filtered to obtain the product. The product obtained was dried at about 45 °C to 50°C to obtain the compound of formula IV. Yield: 5g.
Example 6: Preparation of Carbamic acid, N-[(1R, 2S, 5S)-2-[[2-[(5-chloro-2- pyridinyl)amino]-2-oxoacetyl] amino]-5-[(dimethylamino) carbonyl] cyclohexyl]- 1,1-dimethylethyl ester (compound of formula IV):
To a solution of t-Butyl { ( 1R, 2S, 5S)-2-amino-5 [(dimethylamino)carbonyl] cyclohexyl} carbamate oxalate (compound of formula V, lO.Og) in isopropyl alcohol, triethyl amine (12.34g) was added and the reaction mass was heated to about 50°C to 55°C. At this stage the reaction mass thickens due to gel deposition and stirring becomes difficult. Ethyl 2-((chloropyridin-2-yl) amino)-2-oxoacetate hydrochloride (compound of formula VI, 8.47g) was then added to the reaction mass. The reaction mass was then stirred at about 55°C to 60°C for about 10 hours. The reaction mass was then cooled to about 25°C to 30°C. Water was then added to the reaction mass under stirring and the reaction mass was stirred for 60 minutes. The reaction mass was then filtered to obtain the product. The product obtained was dried at about 45 °C to 50°C for about 12 hours to obtain the compound of formula IV. Yield: 7g.
Comparative Example 1: Preparation of Carbamic acid, N-[(1R, 2S, 5S)-2-[[2-[(5- chloro-2-pyridinyl) amino]-2-oxoacetyl] amino]-5-[(dimethylamino) carbonyl] cyclohexyl]- 1, 1-dimethylethyl ester (compound of formula IV):
To a solution of t-Butyl {(1R, 2S, 5S)-2-amino-5 [(dimethylamino) carbonyl] cyclohexyl} carbamate oxalate (compound of formula V, 25g) in acetonitrile, triethyl amine (30.6g) was added and the reaction mass was heated to about 50°C to 55°C. Ethyl 2-((chloropyridin-2-yl) amino)-2-oxoacetate hydrochloride (compound of formula VI, 21. lg) was then added to the reaction mass. At this stage the reaction mass thicken due to gel deposition and stirring becomes difficult. The reaction mass was then stirred at about 55°C to 60°C for about 6 hours. The reaction mass was then cooled to about 25°C to 30°C for about 12 hours. Water was then added to the reaction mass under stirring and the reaction mass was further cooled to about 0°C to 5°C and stirred for 120 minutes. The reaction mass was then filtered to obtain the product. The product obtained was washed with water and dried at about 45 °C to 50°C for about 12 hours to obtain the compound of formula IV. Yield: 24.0g.

Claims

CLAIMS:
1. A process for the preparation of edoxaban tosylate monohydrate, a compound of formula I comprising:
Figure imgf000025_0001
I
a) reacting a compound of formula V with a compound of formula VI in the presence of a base and a solvent to obtain a compound of formula IV, wherein the solvent is dimethyl sulfoxide;
Figure imgf000025_0002
b) reacting the compound of formula IV with a deprotecting reagent to obtain a compound of formula II or a salt thereof;
Figure imgf000025_0003
c) reacting the compound of formula II or salt thereof with a compound of formula III in the presence of a base to obtain a compound of formula I-A; c) reacting the compound of formula II or salt thereof with a compound of formula III in the presence of a base to obtain a compound of formula I-A;
Figure imgf000026_0001
Ill I-A d) reacting the compound of formula I-A with para toluene sulfonic acid in a solvent to obtain a compound of formula I; and
e) optionally, recrystallizing the compound of formula I with a solvent.
2. The process as claimed in claim 1, wherein the base used in step a) is triethylamine.
3. The process as claimed in claim 1, wherein the base used in step a) is added in one lot.
4. The process as claimed in claim 1, wherein the deprotecting agent used in step b) is selected from the group consisting of ethyl acetate hydrochloride in ethyl acetate solvent, hydrochloric acid in dioxane solvent and hydrochloric acid in acetone solvent.
5. The process as claimed in claim 1, wherein the compound of formula II obtained in step b) is a dihydrochloride salt, a compound of formula II-A.
Figure imgf000026_0002
II-A
6. The process as claimed in claim 1, wherein the base used in step c) is selected from the group consisting of triethyl amine, diisopropyl ethyl amine. 8. The process as claimed in claim 1, wherein the solvent used in recrystallization step e) is selected from the group consisting of acetone, dimethyl sulfoxide, methanol, isopropyl alcohol, methanol water and mixture thereof.
9. The process as claimed in claim 8, wherein edoxaban tosylate monohydrate is crystallized from a solvent mixture of acetone and water.
PCT/IB2020/055950 2019-07-04 2020-06-24 Process for preparation of edoxaban WO2021001728A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP20834439.0A EP3993792A4 (en) 2019-07-04 2020-06-24 Process for preparation of edoxaban
US17/624,595 US20220251112A1 (en) 2019-07-04 2020-06-24 Process for preparation of edoxaban

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201921026759 2019-07-04
IN201921026759 2019-07-04

Publications (1)

Publication Number Publication Date
WO2021001728A1 true WO2021001728A1 (en) 2021-01-07

Family

ID=74100223

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2020/055950 WO2021001728A1 (en) 2019-07-04 2020-06-24 Process for preparation of edoxaban

Country Status (3)

Country Link
US (1) US20220251112A1 (en)
EP (1) EP3993792A4 (en)
WO (1) WO2021001728A1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012002538A1 (en) * 2010-07-02 2012-01-05 第一三共株式会社 Process for preparation of optically active diamine derivative salt
WO2018083213A1 (en) * 2016-11-04 2018-05-11 Esteve Química, S.A. Preparation and purification processes of edoxaban tosylate monohydrate
US20180179226A1 (en) * 2016-12-27 2018-06-28 Apotex Inc. Processes for the Preparation of Edoxaban and Intermediates Thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102348688B (en) * 2009-03-10 2014-07-09 第一三共株式会社 Process for producing diamine derivative
WO2010131663A1 (en) * 2009-05-15 2010-11-18 第一三共株式会社 Oxamide derivative
CN107033163A (en) * 2015-07-16 2017-08-11 浙江海正药业股份有限公司 A kind of Yi Dushaban is to benzene methanesulfonic acid salt novel crystal forms and its preparation method and application
TWI571460B (en) * 2016-03-14 2017-02-21 中化合成生技股份有限公司 Process for producing diamine derivative

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012002538A1 (en) * 2010-07-02 2012-01-05 第一三共株式会社 Process for preparation of optically active diamine derivative salt
WO2018083213A1 (en) * 2016-11-04 2018-05-11 Esteve Química, S.A. Preparation and purification processes of edoxaban tosylate monohydrate
US20180179226A1 (en) * 2016-12-27 2018-06-28 Apotex Inc. Processes for the Preparation of Edoxaban and Intermediates Thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP3993792A4 *

Also Published As

Publication number Publication date
US20220251112A1 (en) 2022-08-11
EP3993792A1 (en) 2022-05-11
EP3993792A4 (en) 2023-07-26

Similar Documents

Publication Publication Date Title
FR2819254A1 (en) NOVEL N- (PHENYLSULFONYL) GLYCINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND USE THEREOF FOR OBTAINING PHARMACEUTICAL COMPOSITIONS
JP2009542785A5 (en)
EP3129356B1 (en) A process for producing enzalutamide
US20150087842A1 (en) Process For The Preparation Of Benzimidazole Derivatives And Salts Thereof
KR101364909B1 (en) Benzimidazole derivatives as calcium channel blockers
WO2017191650A1 (en) Process for the preparation of 5-[[[(2s)-2-amino-3-[4-(aminocarbonyl)-2,6-dimethylphenyl]-1-oxopropyl][(1s)-1-(4-phenyl-1h-imidazol-2-yl)ethyl]amino]methyl-2-methoxybenzoic acid and its polymorphs thereof
AU2018288933A1 (en) Method for preparing intermediate of 4-methoxypyrrole derivative
CN107810189B (en) Process for the preparation of nitrogen mustard derivatives
JP7382647B2 (en) Novel albicidin derivatives, their use and synthesis
CA2885994A1 (en) Process for the preparation of dabigatran etexilate or pharmaceutically acceptable salt thereof
EP3993792A1 (en) Process for preparation of edoxaban
CA2894826C (en) Asymmetric synthesis of a substituted pyrrolidine-2-carboxamide
KR20120101017A (en) Method for manufacturing a 6-substituted-1-methyl-1h-benzimidazole derivative, and manufacturing intermediate from said method
KR100538958B1 (en) Processes for the preparation of 4(5)-amino-5(4)-carboxamidoimidazoles and intermediates thereof
WO2020053795A2 (en) Process for the preparation of acalabrutinib and its intermediates
CA3070240A1 (en) Novel albicidin derivatives, their use and synthesis
JP2022008191A (en) Method for preparing tert-butyl n-((1r, 2s, 5s)-2-((2-((5-chloropyridin-2-yl)amino)-2-oxoacetyl)amino)-5-(dimethylcarbonyl)cyclohexyl)carbamate
WO2018134842A1 (en) Process for the preparation of carbamic acid, n,n'-[[1,1'-biphenyl] -4,4'-diylbis]- 1 h-imidazole-5,2 diyi-(2s)-2,1-pyrrolidinediyl[(1 s)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl]]] bis-,c,c'-dimethyl ester and its salts and polymorphs
CN112272665A (en) Process for preparing sitagliptin
EP3679030B1 (en) A process for preparation of triaminopyrimidine compound and intermediates thereof
US9067868B2 (en) Chemical process for opening ring compounds
KR102184129B1 (en) Production method of intermediate compound for synthesizing medicament
EP3974416A1 (en) Novel albicidin derivatives, their use and synthesis
US20070173647A1 (en) Method for the preparation of dicarboxylic imides
CA2526646A1 (en) Method for synthesising heterocyclic compounds from thiourea derivatives

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20834439

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2020834439

Country of ref document: EP

Effective date: 20220204